Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 6/20 | 0.44 |
| ▸ | MAOA | P21397 | 5/20 | 0.44 |
| ▸ | PPARG | P37231 | 4/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9270208 | 0.81 | HDAC1 (0.46) | PPARGPPARA | |
| SCHEMBL9268768 | 0.74 | GPR52 (0.39) | — | |
| SCHEMBL9269316 | 0.70 | MAOA (0.40) | MAOBMAOAHPGD | |
| SCHEMBL9266806 | 0.70 | MAPT (0.39) | MAOBMAOA | |
| SCHEMBL9266699 | 0.70 | MAPT (0.39) | MAOBMAOA | |
| SCHEMBL839323 | 0.69 | DRD2 (0.71) | FFAR1MAOBMAOAS1PR1S1PR3 | |
| SCHEMBL2096374 | 0.68 | FFAR1 (0.65) | FFAR1MAOBMAOAS1PR1S1PR3 | |
| SCHEMBL1837433 | 0.68 | LMNA (0.66) | FFAR1S1PR1S1PR3 | |
| SCHEMBL9042056 | 0.68 | FFAR1 (0.65) | FFAR1PPARGS1PR1S1PR3PTPN1 | |
| SCHEMBL4361279 | 0.68 | PLA2G4B (0.76) | FFAR1PPARGS1PR1S1PR3PLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5464865-A | Enzyme inhibitors as antiinflammatory agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1995-11-07 | — | — | US | disclosed |